EVENT DETAILS

< Back to All Events

Rain Therapeutics to Participate in H.C. Wainwright’s 3rd Annual Precision Oncology Virtual Conference

November 14, 2022 1:30 AM
Click here for webcast
Description

NEWARK, Calif., November 14, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) ,a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in H.C. Wainwright’s 3rd Annual Precision Oncology Conference on November 14, 2022.

Supporting materials

There are no supporting documents for this event
RAIN_HCW Conference PR
VIEW DOCUMENT
a
VIEW DOCUMENT
a
VIEW DOCUMENT
a
VIEW DOCUMENT
a